Helix BioPharma Corp.
TSX:HBP.TOBiotechnology
-$0.07 today
- Market cap
- $65.69M
- Beta
- -0.29
- P/E (TTM)
- -32.6
- EPS (TTM)
- -$0.04
Volume 0.00M
Average 0.00M
HBP.TO Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Helix BioPharma Corp.TSX: HBP.TO
Common Stock · Q3 FY2026 · quarter ended Apr 2026
Common stock rises 12.0% from a year ago
Common stock stood at CA$180.77M at the end of Q3 FY2026, up 12.0% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +6.7% a year.
Context
- Common stock amounted to 845.4% of total assets at the end of Q3 FY2026, down 15149.4 pp from a year earlier.
- Common stock increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +12.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
CAD · from the balance sheet
- Latest · FY2025
- 179.29M CAD
- Year-over-year change
- +13.1%
- 4-year CAGR
- +6.4%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-07-31 | 179.29M | +13.1% |
| FY2024 | 2024-07-31 | 158.57M | +4.3% |
| FY2023 | 2023-07-31 | 152.07M | +3.1% |
| FY2022 | 2022-07-31 | 147.51M | +5.6% |
| FY2021 | 2021-07-31 | 139.66M | — |
Common Stock vs competitors
How HBP.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +12.0% is the 3rd highest of 5, against a peer median of +12.4%.
- Common stock amounts to 845.4% of total assets for HBP.TO, versus a peer median of 436.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $256.52M USD | -1.4% | -1.2% | 195.5% | |
| Mar 2026 | CA$212.8M CAD | +18.7% | +11.0% | 677.6% | |
| Apr 2026 | CA$180.77M CAD | +12.0% | +6.7% | 845.4% | |
MSCL.TOSatellos Bioscience Inc. | Mar 2026 | $133.98M USD | +71.5% | +41.5% | 178.0% |
| Apr 2026 | CA$125.26M CAD | +6.1% | +2.3% | 8164.7% | |
| Peer median (excluding HBP.TO) | — | +12.4% | +6.6% | 436.6% | |
Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Helix BioPharma Corp.
TSX:HBP.TO
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.